Contrast-Enhanced CT Imaging Features Combined with Clinical Factors to Predict the Efficacy and Prognosis for Transarterial Chemoembolization of Hepatocellular Carcinoma

被引:14
|
作者
Sun, Zhongqi [1 ]
Shi, Zhongxing [2 ]
Xin, Yanjie [1 ]
Zhao, Sheng [1 ]
Jiang, Hao [1 ]
Li, Jinping [1 ]
Li, Jiaping [3 ]
Jiang, Huijie [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Radiol, 246 Xuefu Rd, Harbin 150086, Peoples R China
[2] Harbin Med Univ, Affiliated Hosp 2, Dept Intervent Radiol, Harbin, Peoples R China
[3] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Intervent Oncol, Guangzhou 510080, Peoples R China
基金
中国国家自然科学基金; 中国博士后科学基金;
关键词
Hepatocellular carcinoma; Transarterial chemoembolization; CT; Radiomics; Deep learning; STAGE; PERFORMANCE;
D O I
10.1016/j.acra.2022.12.031
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Rationale and Objectives: Accurate prediction of treatment response to transarterial chemoembolization (TACE) in patients with hepatocellular carcinoma (HCC) is critical for precision treatment. This study aimed to develop a comprehensive model (DLRC) that incorporates contrast-enhanced computed tomography (CECT) images and clinical factors to predict the response to TACE in patients with HCC. Materials and Methods: A total of 399 patients with intermediate-stage HCC were included in this retrospective study. Deep learning and radiomic signatures were established based on arterial phase CECT images, Correlation analysis and the least absolute shrinkage and selection (LASSO) regression analysis were applied for features selection. The DLRC model incorporating deep learning radiomic signatures and clinical factors was developed using multivariate logistic regression. The area under the receiver operating characteristic curve (AUC), calibration curve and decision curve analysis (DCA) were used to evaluate the performance of the models. Kaplan-Meier survival curves based on the DLRC were plotted to assess overall survival in the follow-up cohort (n = 261). Results: The DLRC model was developed using 19 quantitative radiomic features, 10 deep learning features, and 3 clinical factors. The AUC of the DLRC model was 0.937 (95% confidence interval [CI], 0.912-0.962) and 0.909 (95% CI, 0.850-0.968) in the training and validation cohorts, respectively, outperforming models established with two signatures or a single signature (p < 0.05). Stratified analysis showed that the DLRC was not statistically different between subgroups (p > 0.05), and the DCA confirmed the greater net clinical benefit. In addition, multivariable cox regression revealed that DLRC model outputs were independent risk factors for the overall survival (hazard ratios: 1.20, 95% CI: 1.03-1.40; p = 0.019). Conclusion: The DLRC model exhibited a remarkable accuracy in predicting response to TACE, and it can be utilized as a potent tool for precision treatment.
引用
收藏
页码:S81 / S91
页数:11
相关论文
共 50 条
  • [1] Radiomic features at contrast-enhanced CT predict proliferative hepatocellular carcinoma and its prognosis after transarterial chemoembolization
    He, Haifeng
    Feng, Zhichao
    Duan, Junhong
    Deng, Wenzhi
    Wu, Zuowei
    He, Yizi
    Liang, Qi
    Xie, Yongzhi
    SCIENTIFIC REPORTS, 2025, 15 (01):
  • [2] Predictive factors of contrast-enhanced ultrasonography for the response to transarterial chemoembolization in hepatocellular carcinoma
    Park, Kil Hyo
    Kwon, Soon Ha
    Lee, Yong Sub
    Jeong, Soung Won
    Jang, Jae Young
    Lee, Sae Hwan
    Kim, Sang Gyune
    Cha, Sang-Woo
    Kim, Young Seok
    Cho, Young Deok
    Kim, Hong Soo
    Kim, Boo Sung
    Kim, Yong Jae
    CLINICAL AND MOLECULAR HEPATOLOGY, 2015, 21 (02) : 158 - 164
  • [3] Improved quantitative contrast-enhanced ultrasound imaging of hepatocellular carcinoma response to transarterial chemoembolization
    Oezdemir, Ipek
    Shaw, Collette
    Eisenbrey, John R.
    Hoyt, Kenneth
    2019 IEEE 16TH INTERNATIONAL SYMPOSIUM ON BIOMEDICAL IMAGING (ISBI 2019), 2019, : 1737 - 1740
  • [4] Hepatocellular carcinoma treated with transarterial chemoembolization: Evaluation with parametric contrast-enhanced ultrasonography
    Moschouris, Hippocrates
    Malagari, Katerina
    Marinis, Athanasios
    Kornezos, Ioannis
    Stamatiou, Konstantinos
    Nikas, Georgios
    Papadaki, Marina Georgiou
    Gkoutzios, Panagiotis
    WORLD JOURNAL OF RADIOLOGY, 2012, 4 (08): : 379 - 386
  • [5] Dynamic contrast-enhanced CT and clinical features of sarcomatoid hepatocellular carcinoma
    He, Guangming
    Huang, Weiqing
    Zhou, Zhimei
    Wu, Hui
    Tian, Qin
    Tan, Lilian
    Li, Xi
    ABDOMINAL RADIOLOGY, 2023, 48 (10) : 3091 - 3100
  • [6] Dynamic contrast-enhanced CT and clinical features of sarcomatoid hepatocellular carcinoma
    Guangming He
    Weiqing Huang
    Zhimei Zhou
    Hui Wu
    Qin Tian
    Lilian Tan
    Xi Li
    Abdominal Radiology, 2023, 48 : 3091 - 3100
  • [7] mRECIST criteria and contrast-enhanced US for the assessment of the response of hepatocellular carcinoma to transarterial chemoembolization
    Moschouris, Hippocrates
    Malagari, Katerina
    Papadaki, Marina G.
    Kornezos, Ioannis
    Stamatiou, Konstantinos
    Anagnostopoulos, Antonios
    Chatzimichael, Katerina
    Kelekis, Nikolaos
    DIAGNOSTIC AND INTERVENTIONAL RADIOLOGY, 2014, 20 (02) : 136 - 142
  • [8] Contrast-enhanced ultrasound imaging features and clinical characteristics of combined hepatocellular cholangiocarcinoma: comparison with hepatocellular carcinoma and cholangiocarcinoma
    Zhang, Hai-Chun
    Zhu, Ting
    Hu, Rong-Fei
    Wu, Long
    ULTRASONOGRAPHY, 2020, 39 (04) : 356 - 366
  • [9] Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma
    Kono, Yuko
    Lucidarme, Olivier
    Choi, Sang-Hee
    Rose, Steven C.
    Hassanein, Tarek I.
    Alpert, Elliot
    Mattrey, Robert F.
    JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY, 2007, 18 (01) : 57 - 65
  • [10] Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol
    Jiang Bo
    Han Peng
    Zhu LianHua
    Fei Xiang
    Luo YuKun
    BMC Cancer, 21